YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
95 hedge funds and large institutions have $132M invested in Y-mAbs Therapeutics in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
95
Holders Change
+10
Holders Change %
+11.76%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
32
Reduced
30
Closed
10
Calls
$36K
Puts
$11K
Net Calls
+$25K
Net Calls Change
-$23K
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$3.29M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
+$1.84M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.73M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.63M |
| 5 |
Goldman Sachs
New York
|
+$1.44M |
Top Sellers
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.15M |
| 2 |
Millennium Management
New York
|
-$1.99M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.86M |
| 5 |
JPMorgan Chase & Co
New York
|
-$1.07M |
